ArticleGynecologic oncology2016
Sentinel nodes in vulvar cancer: Long-term follow-up of the GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) I.
Article in Gynecologic oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06035068 (Sentinel Lymph Node Mapping and Detection With Indocyanine Green and Spy-Phi Handheld Camera Technology in Early-Stage Vulvar Cancer), which is not on this map. Cited by 79 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Sentinel Lymph Node Mapping and Detection With Indocyanine Green and Spy-Phi Handheld Camera Technology in Early-Stage Vulvar Cancer (PILOT)
Who cites it
79 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Safety of indocyanine green for lymph node mapping in early-stage vulvar cancer: multicenter evaluation and systematic review.Archives of gynecology and obstetrics · 2026Pooled it
- European Society of Gynaecological Oncology Guidelines for the Management of Patients with Vulvar Cancer - Update 2023.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2023Guideline
- Molecular subtypes of stage III vulvar squamous cell carcinoma predict recurrence and survival outcomes.Gynecologic oncology reports · 2026Article
- Long-Term Outcomes, Morbidity and Quality of Life in Node-Negative Early-Stage Vulvar Cancer: Sentinel Node Biopsy versus Inguinofemoral Lymphadenectomy.Geburtshilfe und Frauenheilkunde · 2026Article
- Treatment patterns and outcomes in perineal primary vulvar cancer-a population-based Swedish cohort study.Acta obstetricia et gynecologica Scandinavica · 2026Article
- PET Imaging in Vulvar Cancer: A Literature Review of the Current Evidence and Clinical Applications.Cancers · 2026Review
- Unusual vulvar cancer recurrence after radical vulvectomy with negative margins: a case report.International journal of surgery case reports · 2026Article
- Sentinel lymph node biopsy in vulvar cancer: current evidence, limitations, and future perspectives.Journal of gynecologic oncology · 2026Review
- Association between resection margin and local recurrence in the treatment of primary squamous cell vulvar carcinoma.Journal of gynecologic oncology · 2026Article
- Depth of Invasion of 13 mm or Greater Accurately Predicted the Risk of Having a Node Positivity in Lymphadenectomy for Squamous Vulvar Cancer.The journal of obstetrics and gynaecology research · 2026Article
- Article
- Vulvar and vaginal cancer during pregnancy: A pooled analysis of 15 cases from the International Network on Cancer, Infertility and Pregnancy and review of the literature.Acta obstetricia et gynecologica Scandinavica · 2025Review
- Sentinel Decisions: Current Evidence and Best Practices for Lymph Node Assessment in Vulvar and Cervical Cancers.Gynecologic oncology reports · 2025Review
- Review
- Prognostic Factors for Vulvar Cancer Undergoing Primary Surgery: Case Series from a Single Tertiary Cancer Center.Indian journal of surgical oncology · 2025Article
- Sentinel Lymphonodectomy in Early Vulvar Cancer in Daily Practice: a Multicenter Experience from Germany.Geburtshilfe und Frauenheilkunde · 2025Article
- Current Limitations of Sentinel Node Biopsy in Vulvar Cancer.Current oncology (Toronto, Ont.) · 2025Review
- Controversies in vulvar cancer: revisiting the margin of error.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2025Review
- Follow-up of women after gynecological cancer treatment.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2025Article
- The role of technetium-99m isotope in sentinel lymph node identification in gynecological cancers.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2025Review
19 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIn 2008 GROINSS-V-I, the largest validation trial on the sentinel node (SN) procedure in vulvar cancer, showed that application of the SN-procedure in patients with early-stage vulvar cancer is safe. The current study aimed to evaluate long-term follow-up of these patients regarding recurrences and survival.
methodsFrom 2000 until 2006 GROINSS-V-I included 377 patients with unifocal squamous cell carcinoma of the vulva (T1, <4 cm), who underwent the SN-procedure. Only in case of SN metastases an inguinofemoral lymphadenectomy was performed. For the present study follow-up was completed until March 2015.
resultsThemedian follow-up was 105 months (range 0–179). The overall local recurrence ratewas 27.2% at 5 years and 39.5% at 10 years after primary treatment, while for SN-negative patients 24.6% and 36.4%, and for SN-positive patients 33.2% and 46.4% respectively (p = 0.03). In 39/253 SN-negative patients (15.4%) an inguinofemoral lymphadenectomy was performed, because of a local recurrence. Isolated groin recurrence rate was 2.5% for SN-negative patients and 8.0% for SN-positive patients at 5 years. Disease-specific 10-year survival was 91% for SN-negative patients compared to 65% for SN-positive patients (p b .0001). For all patients, 10-year disease-specific survival decreased from 90% for patients without to 69% for patients with a local recurrence (p b .0001).
Indexed as
Identifiers
26428940What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.